BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Osteoarthritis clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for osteoarthritis: 270 (144 sponsors; 27 newly posted in the last 180 days, 11 stopped in the last 180 days; 18 new-entrant sponsors). Momentum score 7.2, rank 85 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 2, Phase 1 10, Phase 2 26, Phase 3 31, Phase 4 2, N/A 199.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Eli Lilly and Company LLY4P3 2, P2 212
Novo Nordisk A/S NVO2P3 200
Pfizer PFE new entrant2P3 220
Pacira Pharmaceuticals, Inc PCRX4P3 1, P2 1, P1 1, NA 101
Genascence Corporation2P1 1, P3 110
Kolon TissueGene, Inc.2P3 1, P2 100
PharmaResearch Co.,Ltd2P3 1, NA 110
R-Bio2P3 1, NA 101
CELL Technologies Inc.1P3 100
Cellcolabs Clinical SPV Limited1P3 100
CellSeed Inc.1P3 100
Doron Therapeutics Inc.1P3 100
DuoGenic StemCells Corporation (DGSC) new entrant1P3 110
Fujian Shengdi Pharmaceutical Co., Ltd. new entrant1P3 110
GID BIO, Inc.1P3 100
Hangzhou Sciwind Biosciences Co., Ltd. new entrant1P3 110
IBSA Institut Biochimique SA new entrant1P3 110
Lipogems International spa1P3 100
Magellan Stem Cells1P3 100
Medipost, Inc.1P3 100
Nature Cell Co. Ltd.1P3 100
Overseas Pharmaceuticals, Ltd.1P3 100
Paradigm Biopharmaceuticals Ltd.1P3 100
Paradigm Biopharmaceuticals USA (INC)1P3 100
Saol Therapeutics Inc1P3 101

New-entrant sponsors: Pfizer, DuoGenic StemCells Corporation (DGSC), Fujian Shengdi Pharmaceutical Co., Ltd., Hangzhou Sciwind Biosciences Co., Ltd., IBSA Institut Biochimique SA.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P1/P2Nuwacell Biotechnologies Co., Ltd.NCT06741098 A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis( KOA)Knee Osteoarthritisnot yet recruiting162
2026-11-30 est.P3Saol Therapeutics IncNCT07226258 Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee PainOsteoarthritis Knee Painactive not recruiting150
2026-12 est.P3Pacira Pharmaceuticals, Inc PCRXNCT06269705 ZILRETTA in Subjects With Shoulder OsteoarthritisGlenohumeral Osteoarthritisactive not recruiting150
2026-12 est.P3Wuxi Cellular Biopharmaceutical Group Ltd.NCT06570291 Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee OsteoarthritisKnee Osteoarthritisrecruiting520
2026-12-23 est.P3R-BioNCT04427930 Follow-up Study for Participants of Jointstem Phase 3 Clinical TrialKnee Osteoarthritisactive not recruiting129
2026-12-31 est.P2Sclnow Biotechnology Co., Ltd.NCT03383081 The Safety/Efficacy of hUC Mesenchymal Stem Cells(19#iSCLife®-OA) Therapy for Patients With OsteoarthritisOsteoarthritis, Kneerecruiting60
2026-12-31 est.P3TRB ChemedicaNCT04318041 Evaluation of the Structural Modification Effect of Diacerein (Artrodar®) in Knee Osteoarthritic PatientsKnee Osteoarthritisactive not recruiting128
2027-02 est.P2Enlivex Therapeutics Ltd. ENLVNCT07580716 Intra-Articular Allocetra in Patients With Primary Knee OsteoarthritisPrimary Knee Osteoarthritisrecruiting182

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2Pacira Pharmaceuticals, Inc PCRXNCT06884865 A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the KneeOsteoarthritis (OA) of the Kneerecruiting135
2026-11 est.P2KeyBioscience AGNCT06833749 Efficacy and Safety of KBP-336 in Obese Individuals with OsteoarthritisOsteoarthritis in the Knee; Obesityrecruiting600
2026-11 est.P2TBF Genie TissulaireNCT06038331 Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT OsteoarthritisOsteoarthritis Handactive not recruiting14
2026-08-31P24Moving BiotechNCT07225829 A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and OsteoarthritisKnee Osteoarthritis; Synovitis of Kneecompleted130
2026-08 est.P3CELL Technologies Inc.NCT06216028 Bone Marrow Aspirate Concentrate (BMAC) Treatment for Knee OsteoarthritisKnee Osteoarthritis; Musculoskeletal Diseasesnot yet recruiting374
2026-08 est.P2VivaTech International, Inc.NCT02844764 Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the HipOsteoarthritisrecruiting4000
2026-08 est.P2VivaTech International, Inc.NCT02844751 Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the KneeOsteoarthritisrecruiting4000
2026-08 est.P2VivaTech International, Inc.NCT02844738 Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the ShoulderOsteoarthritisrecruiting4000
2026-07-31 est.P2GlaceumNCT06845553 A Study to Assess the Efficacy and Safety of Vutiglabridin in Knee Osteoarthritis PatientsKnee Osteoarthritis (Knee OA)recruiting60
2026-06-01 est.P1/P2BioIntegrateNCT04711304 Evaluation of Safety and Efficacy of Wharton's Jelly Compared to Hyaluronic Acid and Saline for Knee Osteoarthritis.Osteoarthritis, Kneeunknown168

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "osteoarthritis"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.